GLPwatch
Papers (9189)
Page 150 of 154, ranked by citation count.
- Modelling G protein-biased agonism using GLP-1 receptor C-terminal mutations.
- Alterations in one-carbon metabolism in metabolic dysfunction associated steatotic liver disease may be modified by semaglutide.
- Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape.
- Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study.
- Cardiometabolic Profiles of Oral and Subcutaneous Glucagon-Like Peptide-1 Receptor Mono-Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta-Analysis.
- Exenatide through PPARδ improved hepatic insulin resistance in patients of type 2 diabetes mellitus via suppressing pyroptosis.
- The effect of liraglutide on insulin allergy in a patient with glucocorticoid-induced diabetes and multiple sclerosis.
- Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes.
- Psychiatric Adverse Events and Administration Challenges Associated with GLP-1 Receptor Agonists for Weight Loss: A Real-World Analysis.
- Injectable drugs for weight management.
- Renoprotective effects of dulaglutide, a GLP-1 agonist, involving regulation of epithelial-mesenchymal transition in patients with type 2 diabetes and diabetic kidney disease.
- Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP-1 Receptor Agonist Therapy.
- Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective.
- The inhibitor VB-87531 synergizes with tirzepatide and semaglutide for greater weight loss in DIO mice.
- [EFFECTS OF ORALLY AND PARENTERALLY ADMINISTERED ANALOGS OF PEPTIDE HORMONES ON RENAL WATER AND ION TRANSPORT].
- Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus.
- Cardiovascular and brain effects of liraglutide in transthyretin amyloidosis (ATTR) mice models.
- FABP4, marker of worse prognosis in cardiovascular disease, induces neutrophil's proatherogenic phenotype which is modulated by semaglutide.
- Long-Term Effects of Semaglutide and Sitagliptin on Circulating IGFBP-1, IGFBP-3 and IGFBP-rp1: Results from a One-Year Study in Type 2 Diabetes.
- [Treatment of patients with type 2 diabetes mellitus: cardiovascular safety of incretin-based therapy supported by the ELIXA and TECOS trials].
- Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats.
- Study on chitosan/carrageenan core-shell nanoparticles for oral co-administration of insulin/exenatide enhance insulin secretion in type 2 diabetes.
- CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.
- Rational construction of porous cobalt nanoparticle integrated nitrogen doped hollow carbon nanostructures for peptide agonist exendin-4 biosensing.
- A Short-Term Cost-Effectiveness Analysis of Tirzepatide Versus Semaglutide for the Treatment of Obesity in Greece.
- Long-Term Assessment of Weight Loss Medications in a Veteran Population.
- [Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist].
- [Exendin-4 improves impaired endothelial dependent vasodilation in obese rat].
- Effects of GLP1 receptor analogues in obesity with neurodevelopmental disorder: case report of a patient with holoprosencephaly.
- Incretin effect is sufficient for glucose control in developing rats.
- Combination therapy of GLP-1 analogues and insulin: do the benefits outweigh the costs?
- Response to the Letter by Kalra S. et al.
- Comparative Efficacy and Safety of Different Orforglipron Doses in Patients With Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Network Meta-Analysis.
- Effects of Glucagon-Like Peptide-1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review.
- Exenatide added to insulin. Beware the potentially serious adverse effects of exenatide.
- Association of tirzepatide with erectile dysfunction in people with type 2 diabetes.
- Racial Inequity in Prescription of Semaglutide Among Eligible People With HIV.
- Effect of Calorie Restricted Diet Versus Liraglutide on Intrapancreatic Fat Deposition in People With Obesity: A Pilot Study.
- Patient experiences with group consultations when treated with semaglutide for obesity: a qualitative case study in a Danish general practice.
- Examination of quality of life in patients using exenatide with different dimensions.
- Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study.
- Exenatide: excessive weight loss.
- Nmnat2 deficiency in the arcuate nucleus or paraventricular nucleus induces Sarm1-independent neuron loss and liraglutide-reversible obesity.
- The construction of long-acting exendin-4 analog and its hypoglycemic effect in diabetic mice.
- Comment on the Meta-analysis of Liraglutide for Weight Regain: Methodological Considerations.
- Adding liraglutide to diet and exercise to maintain weight loss - is it worth it?
- Glucagon-Like Peptide-1 (GLP-1a) Receptor Agonist Use in Patients Presenting for Gastroenterology Procedures: A Review of Concerns.
- [Possibilities of therapy GLP1 RA for diabetics with nephropathy].
- Effect of Liraglutide combined with Jinlida granules on glycolipid metabolism and islet function of type 2 diabetes mellitus.
- Clinical factors influencing the systolic blood pressure benefits of once-weekly semaglutide in patients with type 2 diabetes.
- Neurological complications associated with rapid weight loss and nutritional deficiencies following GLP-1 agonist use: a case report.
- Semaglutide alleviates ovarian ferroptosis in polycystic ovary syndrome and is associated with reduced GPX4 promoter hypermethylation.
- The Effect of Semaglutide With Lifestyle Intervention on the Physical Health of Patients Treated With Antipsychotic Drugs in a Secure Mental Health Setting: Protocol for an Uncontrolled Pretest-Posttest Pilot Mixed Methods Study.
- Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson's disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study.
- Exenatide attenuates neuroinflammation and rescues sepsis-induced depressive behavior and cognitive dysfunction in a mouse model.
- Liraglutide improves cognitive function by reducing amyloid-beta peptide accumulation and inhibiting inflammation in 5 × FAD mice.
- Liraglutide therapy in an adolescent with Prader‑Willi syndrome and concomitant diabetes mellitus.
- GLP-1-based therapies for obesity: Impact on comorbidities or obesity-related diseases.
- [High dosage GLP-1 analogs are now available].
- Is liraglutide safe and effective in the elderly obese patients?: A single center experience.